Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer

被引：0

作者：

Aredo, J. ^{[1
]}

Padda, S. ^{[1
]}

Kunder, C. ^{[2
]}

Han, S. ^{[1
]}

Wakelee, H. ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期

关键词：

KRAS; Non-small cell lung cancer; disparities; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA03.07

引用

页码：S1133 / S1133

页数：1

共 50 条

[1] KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, Irene
Zugazagoitia, Jon
Herbertz, Stephan
John, William
Paz-Ares, Luis
Schmid-Bindert, Gerald
[J]. LUNG CANCER, 2018, 124 : 53 - 64
[2] Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
Zhang, Jun
Park, Dongkyoo
Shin, Dong M.
Deng, Xingming
[J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2016, 48 (01) : 11 - 16
[3] Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Jacqueline V. Aredo
Sukhmani K. Padda
[J]. Current Treatment Options in Oncology, 2018, 19
[4] Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
Giorgia Maroni
Mahmoud A. Bassal
Indira Krishnan
Chee Wai Fhu
Virginia Savova
Rapolas Zilionis
Valerie A. Maymi
Nicole Pandell
Eva Csizmadia
Junyan Zhang
Barbara Storti
Julio Castaño
Riccardo Panella
Jia Li
Corinne E. Gustafson
Sam Fox
Rachel D. Levy
Claire V. Meyerovitz
Peter J. Tramontozzi
Kimberly Vermilya
Assunta De Rienzo
Stefania Crucitta
Daniela S. Bassères
Marla Weetall
Art Branstrom
Alessandra Giorgetti
Raffaele Ciampi
Marzia Del Re
Romano Danesi
Ranieri Bizzarri
Henry Yang
Olivier Kocher
Allon M. Klein
Robert S. Welner
Raphael Bueno
Maria Cristina Magli
John G. Clohessy
Azhar Ali
Daniel G. Tenen
Elena Levantini
[J]. Communications Biology, 4
[5] Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
Maroni, Giorgia
Bassal, Mahmoud A.
Krishnan, Indira
Fhu, Chee Wai
Savova, Virginia
Zilionis, Rapolas
Maymi, Valerie A.
Pandell, Nicole
Csizmadia, Eva
Zhang, Junyan
Storti, Barbara
Castano, Julio
Panella, Riccardo
Li, Jia
Gustafson, Corinne E.
Fox, Sam
Levy, Rachel D.
Meyerovitz, Claire, V
Tramontozzi, Peter J.
Vermilya, Kimberly
De Rienzo, Assunta
Crucitta, Stefania
Basseres, Daniela S.
Weetall, Marla
Branstrom, Art
Giorgetti, Alessandra
Ciampi, Raffaele
Del Re, Marzia
Danesi, Romano
Bizzarri, Ranieri
Yang, Henry
Kocher, Olivier
Klein, Allon M.
Welner, Robert S.
Bueno, Raphael
Magli, Maria Cristina
Clohessy, John G.
Ali, Azhar
Tenen, Daniel G.
Levantini, Elena
[J]. COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[6] Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, Jacqueline V.
Padda, Sukhmani K.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (08)
[7] KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, Mingying
Xu, Xiaoling
Fan, Yun
[J]. FRONTIERS IN ONCOLOGY, 2021, 11
[8] Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
Li, Yunchang
Hu, Lanlin
Peng, Xinhao
Xu, Huasheng
Tang, Bo
Xu, Chuan
[J]. CANCER DRUG RESISTANCE, 2022, 5 (01) : 129 - 146
[9] Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Shimamura, Takeshi
Chen, Zhao
Soucheray, Margaret
Carretero, Julian
Kikuchi, Eiki
Tchaicha, Jeremy H.
Gao, Yandi
Cheng, Katherine A.
Cohoon, Travis J.
Qi, Jun
Akbay, Esra
Kimmelman, Alec C.
Kung, Andrew L.
Bradner, James E.
Wong, Kwok-Kin
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6183 - 6192
[10] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, Helen
Blackhall, Fiona H.
Lindsay, Colin R.
[J]. EBIOMEDICINE, 2019, 41 : 711 - 716

← 1 2 3 4 5 →